MIRM | Ticker Profile - Titan Protect

MIRM

Mirum Pharmaceuticals, Inc.

Healthcare · Biotechnology · NGM

$93.48

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$5.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-174.43

Based on estimated future earnings — lower means cheaper

Rev Growth

+43.3%

Year-over-year revenue change

Profit Margin

-140.2%

How much profit the company keeps from each dollar of revenue

ROE

-335.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$140.00

+50% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 13 analysts covering this stock

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

https://www.mirumpharma.com

Country: United States Employees: 418 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.701

Excellent risk-adjusted returns

Kelly Fraction

0.1468

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

3.732

Returns exceed worst-case losses — strong risk profile

Annual Return

103.7%

Historical annualised return based on price data

Max Drawdown

-27.8%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.52

Less volatile than the market — more defensive

52W High

$114.99

19% below the year high

52W Low

$43.30

116% above the year low

Avg Volume

988,331

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

17.6%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-13.60

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

133.52

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.09

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.90

Like current ratio but excludes inventory — stricter test

Gross Margin

81.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-39.5%

Profit from core operations before interest and tax

Free Cash Flow

$167M

Positive — the business generates more cash than it spends

Revenue (TTM)

$570M

Total revenue over the last 12 months

Net Income

$-798,841,024

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$185.00

Target Median

$140.00

Target Low

$115.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go